human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection
Sponsors
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Conditions
Parkinson Disease (PD)Parkinson's Disease
Phase 1
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
RecruitingNCT07080775
Start: 2025-08-05End: 2029-08-30Target: 12Updated: 2025-09-11
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
RecruitingNCT07166757
Start: 2025-09-22End: 2029-03-30Target: 90Updated: 2025-12-29